The Race To Yes mobilizes people who support rapid regulatory action to advance safe and effective treatments for Duchenne Muscular Dystrophy and amplifies their collective voice as a mechanism for change. We represent people who believe the participants in the American regulatory system—the FDA, the drug developers, the President, and Congress—have an obligation to urgently and proactively pursue ways to speed safe and effective treatments to patients. Unfortunately, however, the status quo regulatory process—a key step in delivering new treatments—is long, inflexible, and particularly unsuited to support the rapid advances and risk-reward scenario of rare, fatal diseases including Duchenne. As science advances, new opportunities require new, nimble thinking, and the Race to Yes is the people’s movement to make this a priority. Science is difficult enough—our system shouldn’t get in its way.